CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.

Intellia reports a grade 4 liver enzyme elevation in a Nex-Z trial patient; no hospitalization is required, and enrollment ...

Shares of Intellia Therapeutics fell after the company reported a grade 4 adverse event in a study of nex-z, its treatment for hereditary ATTR amyloidosis with polyneuropathy. The stock was down 24% ...

Shares lost a quarter of their value after the company disclosed, in a regulatory filing, signs of liver stress in a study ...

Oppenheimer downgraded Prothena Corporation plc (NASDAQ:PRTA) to Perform from Outperform on May 27 without a price target.

Intellia Therapeutics’ stock may have taken a hit in the wake of details of a grade 4 adverse event in a phase 3 trial, but ...

In the assessment of 12-month price targets, analysts unveil insights for Intellia Therapeutics, presenting an average target ...

Shares of Intellia Therapeutics Inc. (NTLA) plunged 24% on Thursday morning after the company said that a patient in one of ...

Shares of Intellia Therapeutics (NASDAQ: NASDAQ:NTLA) plunged 19% following a safety update from its ongoing Phase 3 MAGNITUDE study. The clinical trial, which is evaluating the company’s gene-editing ...

While an adverse event reported in Intellia’s gene therapy trial was a “non-concern” for analysts, it follows a handful of patient deaths in other trials for the modality and sent the company’s stock ...

Fintel reports that on May 28, 2025, B of A Securities downgraded their outlook for Prothena (NasdaqGS:PRTA) from Neutral to ...

Biogen and City Therapeutics, a privately held developer of RNA-based “trigger molecules,” announced a partnership to develop ...